Mechanistic analyses have demonstrated that OPB-111077 significantly inhibits the STAT3 activation pathway, with antitumor effects against a wide range of human solid and blood tumor cell lines. Here, STAT3 is linked to hematopoietic and lymphoid system neoplasm.